Skip to main
LGVN
LGVN logo

Longeveron (LGVN) Stock Forecast & Price Target

Longeveron (LGVN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Longeveron Inc. holds a promising outlook due to its investigational product, Lomecel-B, which has shown a 60% probability of approval for Hypoplastic Left Heart Syndrome (HLHS) based on meaningful survival benefits observed in the ELPIS-I clinical trial. The company's ELPIS II trial has achieved over 90% enrollment, and a recent positive engagement with the FDA has confirmed its status as a pivotal program, potentially allowing for a Biological License Application (BLA) submission by the second half of 2026. Furthermore, the conservative approach of not modeling sales for Alzheimer's disease or aging-related applications means that successful outcomes in these areas could substantially enhance forecasts and create additional value for investors.

Bears say

Longeveron Inc is projected to face significant financial challenges, with forecasts indicating a net loss of $2.62 per share for 2024, exacerbated by a higher-than-expected weighted average share count. Additionally, the company is grappling with substantial risks regarding the success of its investigational product, Lomecel-B, particularly in clinical trials and potential regulatory approvals, which could impact its future revenue streams. The outlook for 2025 remains negative, with an anticipated net loss of $1.46 per share, reflecting continued operational and market challenges.

Longeveron (LGVN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Longeveron and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Longeveron (LGVN) Forecast

Analysts have given Longeveron (LGVN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Longeveron (LGVN) has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Longeveron (LGVN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.